View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Technology
  2. Data
February 19, 2020

IBM ‘Study Advance’ Tool Aims to Reduce Cost and Time of Clinical Trials

“Track patients longitudinally over multiple years even when they switch plans and includes a strong depth of patient-level detail that reflects the true continuum of care.”

By CBR Staff Writer

IBM have launched a clinical trial study design tool that aims to reduce the cost and time it takes to complete trials by standardising protocols and automating access to real-world patient data.

One of the issues with clinical trials is that they are extremely costly and any change to the protocols at any point of the trial can result in extra costs of on average half a million dollars. For instance a single protocol amendment to the third phase in a clinical trial can extend the running time by several months and significantly increase the financial cost.

Big Blue believes that its IBM Study Advance tool will help researchers reduce the number of amendments they make during trials and reduce the pipeline timeframe for drug treatments.

Rob DiCicco, PharmD, Deputy Chief Health Officer, IBM Watson Health commented in a release that: “Currently, 80% of trials experience delays in recruiting and one out of four amendments were considered completely avoidable. Breakdowns in the clinical trial process, including issues caused by study design decisions, may potentially delay access to life-changing therapies for patients. IBM Study Advance aims to remove the barriers in clinical development to help researchers efficiently bring necessary therapies to patients.”

The Study tool – IBM Study Advance – was unveiled at the 11th annual summit for clinical ops executives, which is taking place in Florida.

 IBM Study Advance

A key part of the tool is its creation of standard protocol templates and version control capabilities. These help to create logs that have high traceability which allows you keep track of any changes made to the trial.

IBM notes that they: “Facilitate the authoring process for your team and help you strategically access the right data assets to eliminate guesswork when it comes to key protocol development decisions, such as evaluating the impact of inclusion and exclusion criteria on the eligible patient population.”

Content from our partners
DTX Manchester welcomes leading tech talent from across the region and beyond
The hidden complexities of deploying AI in your business
When it comes to AI, remember not every problem is a nail

Interestingly IBM says that the service will also open up access to commercial and claims data gleamed from the patient profiles of over 89 million people that are part of US sponsored healthcare beneficiaries.

IBM state that using its Marketscan offering researchers can: “Track patients longitudinally over multiple years even when they switch plans and includes a strong depth of patient-level detail that reflects the true continuum of care.”

See Also: These “Data Trust” Pilots are a Taste of the Future

Topics in this article : , , , ,
Websites in our network
Select and enter your corporate email address Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
  • CIO
  • CTO
  • CISO
  • CSO
  • CFO
  • CDO
  • CEO
  • Architect Founder
  • MD
  • Director
  • Manager
  • Other
Visit our privacy policy for more information about our services, how Progressive Media Investments may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.